Vitalhub Corp. (TSE:VHI - Free Report) - Analysts at Cormark cut their FY2025 EPS estimates for shares of Vitalhub in a research report issued on Thursday, October 31st. Cormark analyst G. Fairweather now forecasts that the company will post earnings per share of $0.18 for the year, down from their previous forecast of $0.22. Cormark has a "Buy" rating and a $10.50 price target on the stock. The consensus estimate for Vitalhub's current full-year earnings is $0.23 per share.
Vitalhub Stock Performance
TSE VHI traded up C$0.05 on Friday, reaching C$10.25. 83,334 shares of the stock traded hands, compared to its average volume of 123,234. Vitalhub has a 12 month low of C$2.87 and a 12 month high of C$10.46. The company has a fifty day moving average price of C$8.87 and a 200-day moving average price of C$7.79. The company has a market cap of C$521.21 million, a price-to-earnings ratio of 93.18, a PEG ratio of 1.18 and a beta of 1.26.
Vitalhub (TSE:VHI - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported C($0.01) earnings per share for the quarter, missing the consensus estimate of C$0.06 by C($0.07). Vitalhub had a net margin of 8.14% and a return on equity of 4.73%. The company had revenue of C$16.24 million for the quarter, compared to the consensus estimate of C$15.39 million.
Vitalhub Company Profile
(
Get Free Report)
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Featured Stories
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
